UCB

Global Cord Blood & Tissue Banking Industry Market Size, Segmentation & Forecast Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 15, 2024
Health, Biotechnology, Catalent, Transplant, Cell, Patient, UCB, LifeCell International, Microsoft Exchange Server, Organization, Regenerative medicine, Cryo-Cell International, Spectrum, Disorder, Umbilical cord, Population growth, Stemcell Technologies, Certification, HSCT, NIH, GMP, Cord blood, The Cooper Companies, Safety, Hematopoietic stem cell transplantation, Artivion, DSM-IV codes, Tissue, Research, Acquisition, Cancer, Leukemia, CBR, Cryopreservation, Cerebral palsy, FDA, CBUS, Sickle cell disease, ClinicalTrials.gov, Registry, Amniotic fluid, Hearing loss, GCBC, MNC, Geography

The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.
  • There are now over 800,000 cord blood units stored in public cord blood banks and more than 6.75 million cord blood and tissue units stored within private banks worldwide.
  • Today, nearly all U.S. cord blood banks and approximately one-third of global cord blood banks offer cord tissue storage.
  • The report presents findings on the following topics:
    Rate per cord blood unit in the U.S. and Europe
    Number of clinical trials, number of published scientific papers, and amount of NIH funding for cord blood research
    Number and types of patents for cord blood, cord tissue, and placental products
    The report presents a comprehensive analysis of the global cord blood and tissue banking market.

UC Berkeley Launches New Molecular Therapeutics Initiative to Accelerate Drug Discovery

Retrieved on: 
Thursday, March 14, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, University, Education, Gene editing, Data science, Drug discovery, Patient, UCB, UC, Artificial intelligence, Chemical biology, Proximity, Cell biology, Cancer, Faculty, Protein, Student, MTI, Doctor of Philosophy, Therapy, Howard Hughes Medical Institute, MTX, University of California, Berkeley, Toxicology, DSM-IV codes, Pharmaceutical industry

The University of California, Berkeley Molecular Therapeutics (MTx) division of the Molecular & Cell Biology department today announced the launch of a new initiative to accelerate drug discovery at the interface of academia and biotech.

Key Points: 
  • The University of California, Berkeley Molecular Therapeutics (MTx) division of the Molecular & Cell Biology department today announced the launch of a new initiative to accelerate drug discovery at the interface of academia and biotech.
  • The UC Berkeley Molecular Therapeutics Initiative (MTI) will create a foundational bridge between fundamental research in rare neurological and metabolic diseases and drug discovery to identify and accelerate novel therapeutic modalities into the clinic.
  • “UC Berkeley is an international nucleus for scientific breakthroughs, such as gene editing and immuno-oncology.
  • “In this way, we are not only advancing R&D but also democratizing it by building industry connections for emerging researchers interested in pursuing a biotech career.”
    The UC Berkeley Molecular Therapeutics Initiative (MTI) seeks to accelerate drug discovery efforts by creating therapeutic modalities that overcome challenges in druggability and address unmet medical need.

FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

Retrieved on: 
Thursday, April 4, 2024
Week, Psoriasis, Ankylosing spondylitis, Patient, UCB, HS, Psoriatic arthritis, Injection, Safety, FDA, Food, Pharmaceutical industry

In addition, a second sBLA for the BIMZELX 2mL device presentations has also been accepted.

Key Points: 
  • In addition, a second sBLA for the BIMZELX 2mL device presentations has also been accepted.
  • "We are excited to share progress on our FDA applications.
  • "In addition, the sBLA for the 2mL device presentations aims to offer increased convenience for patients.
  • Approval of the 2mL device presentations would mean that patients would have an alternative one-injection regimen option."

Ariceum Therapeutics to present new radioligand therapy data at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Thursday, April 4, 2024
Diagnosis, Research, RLT, Radionuclide, UCB, Tissue, Messenger, Abstract (summary), AACR, Therapy, Macrocycle, Poster, Annual general meeting, Peptide, Pharmaceutical industry

The findings describe the selection and initial characterization of macrocyclic peptides against an undisclosed target discovered using UCB's mRNA-display technology platform, ExtremeDiversity™.

Key Points: 
  • The findings describe the selection and initial characterization of macrocyclic peptides against an undisclosed target discovered using UCB's mRNA-display technology platform, ExtremeDiversity™.
  • Macrocyclic peptides are potent ligands for radioligand therapeutics (RLT) that aim to selectively deliver radioisotopes to cancer tissues to eradicate tumor cells while limiting the damage to surrounding tissues.
  • These data have positive implications for the future development of RLT and are a potential game-changer in precision cancer therapy.
  • AACR's Annual Meeting is the perfect industry forum at the forefront of cancer research at which to present our findings."

Ariceum Therapeutics to present new radioligand therapy data at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Thursday, April 4, 2024
Diagnosis, Research, RLT, Radionuclide, UCB, Tissue, Messenger, Abstract (summary), AACR, Therapy, Macrocycle, Poster, Annual general meeting, Peptide, Pharmaceutical industry

The findings describe the selection and initial characterization of macrocyclic peptides against an undisclosed target discovered using UCB's mRNA-display technology platform, ExtremeDiversity™.

Key Points: 
  • The findings describe the selection and initial characterization of macrocyclic peptides against an undisclosed target discovered using UCB's mRNA-display technology platform, ExtremeDiversity™.
  • Macrocyclic peptides are potent ligands for radioligand therapeutics (RLT) that aim to selectively deliver radioisotopes to cancer tissues to eradicate tumor cells while limiting the damage to surrounding tissues.
  • These data have positive implications for the future development of RLT and are a potential game-changer in precision cancer therapy.
  • AACR's Annual Meeting is the perfect industry forum at the forefront of cancer research at which to present our findings."

Advances in Digitalization Presented at the 10th Annual Genedata Biopharma Partner Symposium

Retrieved on: 
Thursday, March 21, 2024
AbbVie, Peptide, ChromeOS, Automation, Sanofi, Organization, Canadian Aviation Regulations, AstraZeneca, Novo Nordisk, MAM, Novartis, GSK, Boehringer Ingelheim, UCB, Vivisection, Roche, NGS, RNA, Knowledge, Merck, Hyphen, Spacecraft, Janssen, Daiichi Sankyo, Digitization, Novozymes, Fine chemical

BASEL, Switzerland, March 21, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful conclusion of the 10th Annual Genedata Biopharma Partner Symposium, held over 2 days from March 6–7, 2024 in Basel, Switzerland. This year's event marked the tenth year of bringing together Genedata customers to share best practices and demonstrate how they increase efficiency and productivity across entire organizations by leveraging the Genedata Biopharma Platform.

Key Points: 
  • BASEL, Switzerland, March 21, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful conclusion of the 10th Annual Genedata Biopharma Partner Symposium, held over 2 days from March 6–7, 2024 in Basel, Switzerland.
  • The Genedata Biopharma Partner Symposium has firmly established itself as a community platform to exchange pioneering work in digitalizing biopharma R&D and establishing best practices based on the Genedata software platform.
  • "The Genedata Biopharma Partner Symposium has firmly established itself as a community platform to exchange pioneering work in digitalizing biopharma R&D and establishing best practices based on the Genedata software platform.
  • The record participation this year underscores the leading position of the Genedata Biopharma Platform within the biopharma industry," said Othmar Pfannes, Ph.D., CEO of Genedata.

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Tuesday, March 5, 2024
Central nervous system, Quarter, EMA, Focal seizure, Research, New Drug Application, UCB, FDA, Partnership, Food, Part, Quantitative electroencephalography, SCN8A, Tremor, SCN2A, Safety, PPR, European Medicines Agency, CNS, EEG, Pharmacokinetics, Part 1, Patient, Essential tremor, Medicine, Epilepsy, DEE, Trial of the century, NDA, Ageing, Central nervous system disease, Seizure, Pharmaceutical industry

Fourth Quarter and Full Year 2023 Financial Results:

Key Points: 
  • Fourth Quarter and Full Year 2023 Financial Results:
    As of December 31, 2023, Praxis had $81.3 million in cash and cash equivalents, compared to $100.5 million in cash, cash equivalents and marketable securities as of December 31, 2022.
  • Research and development expenses were $18.4 million for the fourth quarter of 2023, compared to $28.3 million for the fourth quarter of 2022.
  • General and administrative expenses were $9.9 million for the fourth quarter of 2023, compared to $13.1 million for the fourth quarter of 2022.
  • Praxis incurred a net loss of $26.9 million for the fourth quarter of 2023, including $5.7 million of stock-based compensation expense, compared to $41.2 million for the fourth quarter of 2022, including $6.4 million of stock-based compensation expense.

Asha Therapeutics to Present at AD/PD™ 2024 International Conference and Announces Clinical Development Plan for Lead Programs Anticipated to Enter Clinical Trials this Year and Welcomes Two New SAB Members

Retrieved on: 
Friday, March 8, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Oncology, Other Science, Other Technology, Research, Software, General Health, Science, Data Management, Clinical Trials, Community health, GSK, AbbVie, Huntington's disease, University, Mathematics, Emory University, Behavioral neurology, Pathology, School, Alzheimer's disease, Johnson & Johnson, Drug design, Gold, Bristol Myers Squibb, Johns Hopkins, Disorder, Psychiatry, Derek, UCB, Computer science, American Neurological Association, Asha, Parkinson's Foundation, Conference, Chemistry, Safety, Amelioration, CNS, Behavioural sciences, Medical school, MD, Neurology, Patient, Florida College, Disease, Publication, DRS, Pharmaceutical industry

Dr. Heckmann’s presentation is titled ASHA-091: Novel Pharmacological Targeting of Mitochondrial Dysfunction to Ameliorate Parkinson’s & Alzheimer’s Disease Pathology.

Key Points: 
  • Dr. Heckmann’s presentation is titled ASHA-091: Novel Pharmacological Targeting of Mitochondrial Dysfunction to Ameliorate Parkinson’s & Alzheimer’s Disease Pathology.
  • ASHA-091 restores normal mitochondrial function and has demonstrated disease modifying efficacy as a functional cure in preclinical disease models.
  • In preparation for clinical transition, Asha has appointed Dr. Michael Gold and Dr. Allan Levey to their Scientific Advisory Board.
  • Their expertise comes at a pivotal moment for Asha as we transition our first-in-class lead programs designed using our PRISM™ technology to clinical trials.

Seizure Action Plan Awareness Week Set For February 12-19

Retrieved on: 
Wednesday, February 7, 2024
SAP, Fear, UCB, Seizure, Caregiver, Patient, Epilepsy, Social media, Watchful waiting, Organization, Drug

BATON ROUGE, La., Feb. 7, 2024 /PRNewswire/ -- The Seizure Action Plan Coalition , a collaboration managed by Epilepsy Alliance America , will hold the 4th Annual Seizure Action Plan (SAP) Awareness Week Feb. 12-19, 2024.

Key Points: 
  • BATON ROUGE, La., Feb. 7, 2024 /PRNewswire/ -- The Seizure Action Plan Coalition , a collaboration managed by Epilepsy Alliance America , will hold the 4th Annual Seizure Action Plan (SAP) Awareness Week Feb. 12-19, 2024.
  • Let's unite to raise awareness during Seizure Action Plan Awareness Week," said Brad Chapman, Head of U.S. Epilepsy and Rare Syndromes.
  • The Seizure Action Plan Coalition website has tools and resources from its awareness partners for individuals with epilepsy and their families.
  • For more information on Seizure Action Plan Awareness Week, visit SeizureActionPlans.org today.

DIA Europe 2024 to Confront Sustainability, Innovation, and Collaboration in Healthcare

Retrieved on: 
Tuesday, January 30, 2024
Medical Devices, Hospitals, Cardiology, Other Health, Biotechnology, Alternative Medicine, General Health, Pharmaceutical, Health, Oncology, Real-World Evidence, Partnership, Diamond, Policy, Civil service commission, Senior, MHRA, Research, UCB, Government, Interface, Learning, Digital transformation, Véronique, Emer Cooke, Patient, Institute of technology, EMA, Personalized medicine, European Commission, Corporate Affairs, World Health Organization, Research fellow, ICMRA, Drug development, Executive, Medication, European Medicines Agency, Artificial intelligence, Medicine, Innovation, Data analysis, Data science, HMA, WHO, Pharmaceutical industry

DIA , a global organization of life sciences professionals, will emphasize how collaboration and innovation can support sustainability in healthcare at DIA Europe 2024 , to be held March 12-14 at Square Brussels Convention Centre in Brussels.

Key Points: 
  • DIA , a global organization of life sciences professionals, will emphasize how collaboration and innovation can support sustainability in healthcare at DIA Europe 2024 , to be held March 12-14 at Square Brussels Convention Centre in Brussels.
  • Now in its 36th year, DIA Europe will feature discussions on the environmental footprint of pharmaceuticals and drug development.
  • "Sustainability is one of the defining challenges in healthcare today," said Ania Mitan, DIA's Senior Vice President and Managing Director, EMEA and India.
  • DIA is celebrating 60 years of bringing together leading minds to foster innovation, collaboration, and advancement in global healthcare.